Puma Biotechnology/PBYI

$6.46

-0.3%
-
1D1W1MYTD1YMAX

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. It is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Ticker

PBYI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alan Auerbach

Employees

192

Headquarters

Los angeles, United States

PBYI Metrics

BasicAdvanced
$311.59M
Market cap
88.96
P/E ratio
$0.07
EPS
1.32
Beta
-
Dividend rate

What the Analysts think about PBYI

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 3 analysts.
27.71% downside
High $8.00
Low $2.00
$6.46
Current price
$4.67
Average price target

PBYI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.16% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$56.1M
2.94%
Net income
$5.7M
171.43%
Profit margin
10.16%
163.9%

PBYI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.12
$0.03
$0.05
$0.12
-
Expected
$0.00
-$0.07
$0.01
$0.08
$0.30
Surprise
-3,700.36%
-142.86%
566.67%
56.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Puma Biotechnology stock

Buy or sell Puma Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing